Ultragenyx Pharmaceutical Targets 2027 Profitability After Deep Cuts and Gene Therapy Launches
Ultragenyx Pharmaceutical (RARE) aims for profitability by 2027, driven by gene therapy launches and potential next-gen versions of Crysvita. CEO Kakkis reported positive early interest in FAYUVI and GENGLYCOS, with launch data expected in January. The company is also discussing setrusumab's next steps with the FDA after a missed endpoint in the ORBIT study and is studying DTX301 for ornithine transcarbamylase deficiency.
How this was made

The 30-second read
Why it matters
The key trading angle is the combination of (1) regulatory uncertainty for setrusumab after a missed primary endpoint and (2) staged visibility into gene-therapy performance, with profitability targeted for 2027 after deep cuts.
Market read
Traders may reprice the probability-weighted path for setrusumab and adjust expectations for how quickly FAYUVI/GENGLYCOS launches can contribute to profitability.
What to watch
The article emphasizes that Ultragenyx will not issue product-specific forecasts until it has about six quarters of launch experience, which can delay consensus model updates and keep near-term expectations volatile.
Background
Ultragenyx is commercializing Crysvita and Mepsevii and launching gene therapies FAYUVI and GENGLYCOS, while also pursuing setrusumab after ORBIT missed an endpoint.
Ticker impact
Ultragenyx CEO discusses setrusumab next steps with FDA after ORBIT missed its fracture-rate endpoint and outlines gene-therapy launch plans toward 2027 profitability.
Likely mixed-to-negative near term as investors weigh FDA path uncertainty for setrusumab against progress in gene-therapy launches.
The article flags a missed primary endpoint and no timeline for an FDA update, while also stating launches are going well and that profitability targets depend on accumulating launch experience.
Market effects
Highlights ongoing regulatory sensitivity to surrogate endpoints in rare-disease bone disorders and the importance of trial design for FDA acceptance.
Limited, primarily affects US-listed rare-disease biotech sentiment.
Moderate for gene-therapy peers via read-across on launch execution and post-endpoint FDA engagement.
Counterpoint
Investors may discount the ORBIT miss if post hoc fracture reductions and bone mineral density improvements strengthen the FDA discussion, making setrusumab risk less binary than implied.
Key entities
- companyUltragenyx Pharmaceutical
NASDAQ-listed rare-disease biotech; CEO comments on setrusumab FDA next steps and gene-therapy launch progress.
- regulatorFood and Drug Administration
Agency Ultragenyx is discussing next steps with after ORBIT missed its fracture-rate endpoint.
- productFAYUVI
Gene therapy launch referenced as generating more immediate interest from Sanfilippo syndrome families.
- productGENGLYCOS
Gene therapy launch referenced as going well, with launch information planned for January.
- programsetrusumab
OI-related therapy discussed with FDA after ORBIT missed its fracture-rate endpoint.


